Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2017, Article ID 6045017, 4 pages
https://doi.org/10.1155/2017/6045017
Case Report

Treatment of Generalized Anxiety Disorder with Gabapentin

Department of Psychiatry and Psychology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA

Correspondence should be addressed to Matej Markota; ude.oyam@jetam.atokram

Received 6 September 2017; Revised 14 November 2017; Accepted 28 November 2017; Published 14 December 2017

Academic Editor: Toshiya Inada

Copyright © 2017 Matej Markota and Robert J. Morgan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Singh, M. J. Field, P. Ferris et al., “The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine,” Psychopharmacology, vol. 127, no. 1, pp. 1–9, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. A. C. Pande, J. R. T. Davidson, J. W. Jefferson et al., “Treatment of social phobia with gabapentin: A placebo-controlled study,” Journal of Clinical Psychopharmacology, vol. 19, no. 4, pp. 341–348, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. A. C. Pande, M. H. Pollack, J. Crockatt et al., “Placebo-controlled study of gabapentin treatment of panic disorder,” Journal of Clinical Psychopharmacology, vol. 20, no. 4, pp. 467–471, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. R. K. Berlin, P. M. Butler, and M. D. Perloff, “Gabapentin therapy in psychiatric disorders: A systematic review,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 17, no. 5, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Chouinard, L. Beauclair, and M.-C. Belanger, “Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders,” The Canadian Journal of Psychiatry, vol. 43, no. 3, article 305, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. M. H. Pollack, J. Matthews, and E. L. Scott, “Gabapentin as a potential treatment for anxiety disorders,” The American Journal of Psychiatry, vol. 155, no. 7, pp. 992-993, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Wills, P. Reynolds, E. Chu et al., “Clinical outcomes in newer anticonvulsant overdose: a poison center observational study,” Journal of Medical Toxicology, vol. 10, no. 3, pp. 254–260, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Boneva, T. Brenner, and Z. Argov, “Gabapentin may be hazardous in myasthenia gravis,” Muscle & Nerve, vol. 23, no. 8, pp. 1204–1208, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Flamm, S. Sachdev, and F. Dufresne, “Gabapentin-induced bullous pemphigoid,” The Journal of the American Osteopathic Association, vol. 117, no. 3, pp. 191–193, 2017. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Sills, “The mechanisms of action of gabapentin and pregabalin,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 108–113, 2006. View at Publisher · View at Google Scholar
  11. Ç. Eroglu, N. J. Allen, M. W. Susman et al., “Gabapentin receptor α2δ-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis,” Cell, vol. 139, no. 2, pp. 380–392, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. C. P. Taylor, “Mechanisms of action of gabapentin,” Revue Neurologique, suppl. 1, pp. S39–S45, 1997. View at Google Scholar
  13. P. Jenner, J. A. Pratt, and C. D. Marsden, “Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT.,” Advances in Neurology, vol. 43, pp. 629–643, 1986. View at Google Scholar · View at Scopus
  14. J. G. Leung, D. Hall-Flavin, S. Nelson, K. A. Schmidt, and K. M. Schak, “Role of gabapentin in the management of alcohol withdrawal and dependence,” Annals of Pharmacotherapy, vol. 49, no. 8, pp. 897–906, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. J. G. Bramness, P. Sandvik, A. Engeland, and S. Skurtveit, “Does Pregabalin (Lyrica ®) help patients reduce their use of benzodiazepines? A comparison with gabapentin using the norwegian prescription database,” Basic & Clinical Pharmacology & Toxicology, vol. 107, no. 5, pp. 883–886, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Markota, T. A. Rummans, J. M. Bostwick, and M. I. Lapid, “Benzodiazepine Use in Older Adults: Dangers, Management, and Alternative Therapies,” Mayo Clinic Proceedings, vol. 91, no. 11, pp. 1632–1639, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. T. L. Mersfelder and W. H. Nichols, “Gabapentin: Abuse, Dependence, and Withdrawal,” Annals of Pharmacotherapy, vol. 50, no. 3, pp. 229–233, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Victorri-Vigneau, M. Guerlais, and P. Jolliet, “Abuse, dependency and withdrawal with gabapentin: A first case report,” Pharmacopsychiatry, vol. 40, no. 1, pp. 43-44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. P. Kruszewski, R. P. Paczynski, and D. A. Kahn, “Gabapentin-induced delirium and dependence,” Journal of Psychiatric Practice, vol. 15, no. 4, pp. 314–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. L. Reccoppa, R. Malcolm, and M. Ware, “Gabapentin abuse in inmates with prior history of cocaine dependence,” American Journal on Addictions, vol. 13, no. 3, pp. 321–323, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. M. E. Buttram, S. P. Kurtz, R. C. Dart, and Z. R. Margolin, “Law enforcement-derived data on gabapentin diversion and misuse, 2002–2015: diversion rates and qualitative research findings,” Pharmacoepidemiology and Drug Safety, vol. 26, no. 9, pp. 1083–1086, 2017. View at Publisher · View at Google Scholar